Mendus Q2 2025: Nearing phase III-readiness - Redeye

Redeye provides its comment on Mendus’ Q2 2025 report. Mendus is approaching phase III-readiness with vididencel in AML in H2 2025e, and we suspect business development will play a significant role in securing late-stage financing. We update our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123969/mendus-q2-2025-nearing-phase-iii-readiness?utm_source=finwire&utm_medium=RSS